Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Andjelija Zivanovic Bujak"'
Autor:
Andjelija Zivanovic Bujak, Chen-Fang Weng, Maria João Silva, Miriam Yeung, Louisa Lo, Sarah Ftouni, Cassandra Litchfield, Yi-An Ko, Keilly Kuykhoven, Courtney Van Geelen, Sushma Chandrashekar, Mark A Dawson, Sherene Loi, Stephen Q Wong, Sarah-Jane Dawson
Publikováno v:
PLoS Medicine, Vol 17, Iss 10, p e1003363 (2020)
BackgroundMetastatic breast cancer (mBC) is a heterogenous disease with increasing availability of targeted therapies as well as emerging genomic markers of therapeutic resistance, necessitating timely and accurate molecular characterization of disea
Externí odkaz:
https://doaj.org/article/400cac0c048b46efa33e37a54f2ee850
Autor:
Peter Savas, Louisa L. Lo, Stephen J. Luen, Elizabeth F. Blackley, Jason Callahan, Kate Moodie, Courtney T. van Geelen, Yi-An Ko, Chen-Fang Weng, Lironne Wein, Maria João Silva, Andjelija Zivanovic Bujak, Miriam M. Yeung, Sarah Ftouni, Rodney J. Hicks, Prudence A. Francis, Chee Khoon Lee, Sarah-Jane Dawson, Sherene Loi
Publikováno v:
Cancer Discovery. 12:2058-2073
There is limited knowledge on the benefit of the α-subunit–specific PI3K inhibitor alpelisib in later lines of therapy for advanced estrogen receptor–positive (ER+) HER2− and triple-negative breast cancer (TNBC). We conducted a phase II multic
Autor:
Sherene Loi, Sarah-Jane Dawson, Chee Khoon Lee, Prudence A. Francis, Rodney J. Hicks, Sarah Ftouni, Miriam M. Yeung, Andjelija Zivanovic Bujak, Maria João Silva, Lironne Wein, Chen-Fang Weng, Yi-An Ko, Courtney T. van Geelen, Kate Moodie, Jason Callahan, Elizabeth F. Blackley, Stephen J. Luen, Louisa L. Lo, Peter Savas
Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b2063ace12f0c65ebe9bfaecac196fd
https://doi.org/10.1158/2159-8290.22541071.v1
https://doi.org/10.1158/2159-8290.22541071.v1
Autor:
Sherene Loi, Sarah-Jane Dawson, Chee Khoon Lee, Prudence A. Francis, Rodney J. Hicks, Sarah Ftouni, Miriam M. Yeung, Andjelija Zivanovic Bujak, Maria João Silva, Lironne Wein, Chen-Fang Weng, Yi-An Ko, Courtney T. van Geelen, Kate Moodie, Jason Callahan, Elizabeth F. Blackley, Stephen J. Luen, Louisa L. Lo, Peter Savas
Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::558da9ece4db0f131511beb7094e135a
https://doi.org/10.1158/2159-8290.22541074
https://doi.org/10.1158/2159-8290.22541074
Autor:
Geoffrey J. Lindeman, Jane E. Visvader, Daniel H.D. Gray, Sarah-Jane Dawson, Andjelija Zivanovic Bujak, Miriam M. Yeung, Belinda Yeo, Avraham Travers, Leanne Taylor, Gordon K. Smyth, Zhen R. Siow, Maria João Silva, Kylie Shackleton, Mark A. Rosenthal, Andrew W. Roberts, Bhupinder Pal, Anand Murugasu, Kate Moodie, G. Bruce Mann, He K. Liu, Danny Liew, Luke C. Gandolfo, Sarah Ftouni, Jayesh Desai, Alice R.T. Bergin, Antonia N. Policheni, Louisa L. Lo, Charis E. Teh, François Vaillant, James R. Whittle, Sheau W. Lok
Supplementary Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6754aaf665e0ea4455755597cc9c2c12
https://doi.org/10.1158/2159-8290.22532875
https://doi.org/10.1158/2159-8290.22532875
Autor:
Geoffrey J. Lindeman, Jane E. Visvader, Daniel H.D. Gray, Sarah-Jane Dawson, Andjelija Zivanovic Bujak, Miriam M. Yeung, Belinda Yeo, Avraham Travers, Leanne Taylor, Gordon K. Smyth, Zhen R. Siow, Maria João Silva, Kylie Shackleton, Mark A. Rosenthal, Andrew W. Roberts, Bhupinder Pal, Anand Murugasu, Kate Moodie, G. Bruce Mann, He K. Liu, Danny Liew, Luke C. Gandolfo, Sarah Ftouni, Jayesh Desai, Alice R.T. Bergin, Antonia N. Policheni, Louisa L. Lo, Charis E. Teh, François Vaillant, James R. Whittle, Sheau W. Lok
Supplementary Tables S1-5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1eecbfe26877eb276ea56a2a6c57e6a7
https://doi.org/10.1158/2159-8290.22532860
https://doi.org/10.1158/2159-8290.22532860
Autor:
Geoffrey J. Lindeman, Jane E. Visvader, Daniel H.D. Gray, Sarah-Jane Dawson, Andjelija Zivanovic Bujak, Miriam M. Yeung, Belinda Yeo, Avraham Travers, Leanne Taylor, Gordon K. Smyth, Zhen R. Siow, Maria João Silva, Kylie Shackleton, Mark A. Rosenthal, Andrew W. Roberts, Bhupinder Pal, Anand Murugasu, Kate Moodie, G. Bruce Mann, He K. Liu, Danny Liew, Luke C. Gandolfo, Sarah Ftouni, Jayesh Desai, Alice R.T. Bergin, Antonia N. Policheni, Louisa L. Lo, Charis E. Teh, François Vaillant, James R. Whittle, Sheau W. Lok
Supplementary Table S8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61a1e6c1ba1fc7c8f077c040086dea60
https://doi.org/10.1158/2159-8290.22532866
https://doi.org/10.1158/2159-8290.22532866
Autor:
Geoffrey J. Lindeman, Jane E. Visvader, Daniel H.D. Gray, Sarah-Jane Dawson, Andjelija Zivanovic Bujak, Miriam M. Yeung, Belinda Yeo, Avraham Travers, Leanne Taylor, Gordon K. Smyth, Zhen R. Siow, Maria João Silva, Kylie Shackleton, Mark A. Rosenthal, Andrew W. Roberts, Bhupinder Pal, Anand Murugasu, Kate Moodie, G. Bruce Mann, He K. Liu, Danny Liew, Luke C. Gandolfo, Sarah Ftouni, Jayesh Desai, Alice R.T. Bergin, Antonia N. Policheni, Louisa L. Lo, Charis E. Teh, François Vaillant, James R. Whittle, Sheau W. Lok
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497f38835c1eaa1caced8bc6e550c238
https://doi.org/10.1158/2159-8290.22532878
https://doi.org/10.1158/2159-8290.22532878
Autor:
Peter Savas, Louisa Lisa Lo, Stephen James Luen, Elizabeth Fay Blackley, Courtney Templeton van Geelen, Yi-An Ko, Kate Moodie, Jason William Callahan, Chen-Fang Weng, Andjelija Zivanovic Bujak, Miriam Manning Yeung, Sarah Ftouni, Prudence Anne Francis, Sarah-Jane Dawson, Sherene Loi
Publikováno v:
Cancer Research. 82:P1-18
Background: The PI3Kα subunit specific inhibitor alpelisib in combination with fulvestrant is approved in advanced breast cancer harbouring PIK3CA mutations, but predictive biomarkers are lacking. We performed a phase II single arm study of alpelisi
Autor:
Kylie Shackleton, G. Bruce Mann, Jayesh Desai, Sarah Ftouni, Maria Joao Silva, Anand Murugasu, Andrew W. Roberts, Sarah-Jane Dawson, Mark Rosenthal, Kate Moodie, Bhupinder Pal, François Vaillant, Daniel H.D. Gray, Jane E. Visvader, Alice Ruth Bergin, Andjelija Zivanovic Bujak, Geoffrey J. Lindeman, Charis E Teh, Sheau W. Lok, James R. Whittle, Miriam M. Yeung, Luke C. Gandolfo, Louisa L. Lo, Zhen Rong Siow, Avraham Travers, Gordon K. Smyth, Belinda Yeo, Leanne S. Taylor, Antonia N. Policheni, Danny Liew, He K. Liu
Publikováno v:
Cancer Discovery. 9:354-369
Venetoclax, a potent and selective BCL2 inhibitor, synergizes with endocrine therapy in preclinical models of ER-positive breast cancer. Using a phase Ib 3 + 3 dose-escalation and expansion study design, 33 patients with ER and BCL2-positive metastat